ROCHE HOLDING AG
-------------- ----------------------------------------------------- --------
Glofitamab step-up dosing (SUD): Complete
response rates in updated efficacy
data in heavily pretreated relapsed/refractory
(R/R) non-Hodgkin lymphoma (NHL) patients
Glofitamab (pts). 7519
-------------- ----------------------------------------------------- --------
Promising tolerability and efficacy
results from dose-escalation in an
ongoing phase Ib/II study of mosunetuzumab
(M) with polatuzumab vedotin (Pola)
in patients (pts) with relapsed/refractory
(R/R) B-cell non-Hodgkin's lymphoma
Mosunetuzumab (B-NHL). 7520
-------------- ----------------------------------------------------- --------
Polatuzumab vedotin (Pola) + rituximab
(R) + lenalidomide (Len) in patients
(pts) with relapsed/refractory (R/R)
diffuse large B-cell lymphoma (DLBCL):
Polivy Primary analysis of a phase 1b/2 trial. 7512
-------------- ----------------------------------------------------- --------
Measurable residual disease response
Venclexta/ in acute myeloid leukemia treated with
Venclyxto venetoclax and azacitidine. 7018
-------------- ----------------------------------------------------- --------
Breast cancer
-------------------------------------------------------------------------------
acelERA Breast Cancer (BC): Phase II
study evaluating efficacy and safety
of giredestrant (GDC-9545) versus physician's
choice of endocrine monotherapy in
patients (pts) with oestrogen receptor-positive,
HER2-negative (ER+/HER2-) locally advanced
Giredestrant or metastatic breast cancer (LA/mBC). TPS1100
-------------- ----------------------------------------------------- --------
persevERA Breast Cancer (BC): Phase
III study evaluating the efficacy and
safety of giredestrant (GDC-9545) +
palbociclib versus letrozole + palbociclib
in patients (pts) with oestrogen-receptor-positive,
HER2-negative locally advanced or metastatic
Giredestrant BC (ER+/HER2-- LA/mBC). TPS1103
-------------- ----------------------------------------------------- --------
Safety and activity of single-agent
giredestrant (GDC-9545) from a phase
Ia/b study in patients (pts) with oestrogen
receptor-positive (ER+), HER2-negative
locally advanced/metastatic breast
Giredestrant cancer (LA/mBC). 1017
-------------- ----------------------------------------------------- --------
Evaluation of pharmacodynamic (PD)
and biologic activity in a preoperative
window-of-opportunity (WOO) study of
giredestrant (GDC-9545) in postmenopausal
patients (pts) with oestrogen receptor-positive,
HER2-negative (ER+/HER2--) operable
Giredestrant breast cancer (BC). 577
-------------- ----------------------------------------------------- --------
Safety of trastuzumab emtansine (T-DM1)
in patients (pts) with HER2-positive
locally advanced or metastatic breast
cancer (mBC): Final results from KAMILLA
Kadcyla Cohorts 1 (global) and 2 (Asia). 1039
-------------- ----------------------------------------------------- --------
Potential non-drug cost differences
associated with the use of the fixed-dose
combination of pertuzumab and trastuzumab
for subcutaneous injection (PH FDC
SC) in the treatment of HER2-positive
early breast cancer patients in Western
Phesgo Europe and the United States. 544
-------------- ----------------------------------------------------- --------
The tumour microenvironment (TME) and
atezolizumab + nab-paclitaxel (A+nP)
activity in metastatic triple-negative
Tecentriq breast cancer (mTNBC): IMpassion130. 1006
-------------- ----------------------------------------------------- --------
Colon cancer
-------------------------------------------------------------------------------
Phase Ib/II open-label, randomised
evaluation of atezolizumab (atezo)
+ Imprime PGG (Imprime) + bevacizumab
(bev) vs regorafenib (rego) in MORPHEUS:
Microsatellite-stable (MSS) metastatic
Tecentriq colorectal cancer (mCRC). 3559
-------------- ----------------------------------------------------- --------
Liver cancer
-------------------------------------------------------------------------------
IMbrave150: Exploratory analysis to
examine the association between treatment
response and overall survival (OS)
in patients (pts) with unresectable
hepatocellular carcinoma (HCC) treated
with atezolizumab (atezo) + bevacizumab
Tecentriq (bev) versus sorafenib (sor). 4071
-------------- ----------------------------------------------------- --------
IMbrave150: Exploratory efficacy and
safety results of hepatocellular carcinoma
(HCC) patients (pts) with main trunk
and/or contralateral portal vein invasion
(Vp4) treated with atezolizumab (atezo)
+ bevacizumab (bev) versus sorafenib
Tecentriq (sor) in a global Ph III study. 4073
-------------- ----------------------------------------------------- --------
Personalised healthcare and health equity
-------------------------------------------------------------------------------
Association of electronic-health record
(EHR)-derived race with BRCA testing
in patients (pts) with breast cancer
(BC) with similar genetic ancestry
(GA) in a clinicogenomic database (CGDB). 6524
-------------------------------------------------------------------- --------
Racial, ethnic, and socioeconomic disparities
in treatment outcomes in patients (pts)
with diffuse large B-cell lymphoma
(DLBCL): A U.S. real-world study using
a de-identified electronic health record
(EHR)-derived database. e18514
-------------- ----------------------------------------------------- --------
Tumour agnostic
-------------------------------------------------------------------------------
Alpha-T: An innovative decentralised
(home-based) phase 2 trial of alectinib
in ALK-positive (ALK+) solid tumours
Alecensa in a histology-agnostic setting. TPS3155
-------------- ----------------------------------------------------- --------
Clinical activity and safety of the
RET inhibitor pralsetinib in patients
with RET fusion-positive solid tumours:
Gavreto Update from the ARROW trial 3079
-------------- ----------------------------------------------------- --------
Rozlytrek, Tumour-agnostic precision immuno-oncology TPS3154
Alecensa, and somatic targeting rationale for
Tecentriq, you (TAPISTRY): a novel platform umbrella
Ipatasertib, trial.
Kadcyla,
Inavolisib
-------------- ----------------------------------------------------- --------
Rozlytrek, A study evaluating targeted therapies TPS1588
Inavolisib, in participants who have advanced solid
Ipatasertib, tumours with genomic alterations or
Tecentriq, protein expression patterns predictive
Kadcyla, of response (MyTACTIC).
Perjeta,
Herceptin
-------------- ----------------------------------------------------- --------
Blueprint Medicines and Roche are co-developing Gavreto (pralsetinib)
globally, excluding Greater China.* Blueprint Medicines and Genentech, a
wholly-owned member of the Roche Group, are commercialising Gavreto in
the US and Roche has exclusive commercialisation rights for Gavreto
outside of the US, excluding Greater China.*
Greater China encompasses Mainland China, Hong Kong, Macau and Taiwan.
CStone Pharmaceuticals retains all rights to the development and
commercialisation of Gavreto in Greater China under its existing
collaboration with Blueprint Medicines.
All trademarks used or mentioned in this release are protected by law.
Blueprint Medicines, Gavreto and associated logos are trademarks of
Blueprint Medicines Corporation.
About Roche in Oncology
Roche has been working to transform cancer care for more than 50 years,
bringing the first specifically designed anti-cancer chemotherapy drug,
fluorouracil, to patients in 1962. Roche's commitment to developing
innovative medicines and diagnostics for cancers remains steadfast. The
Roche Group's portfolio of innovative cancer medicines includes:
Alecensa(R)(alectinib); Avastin(R)(bevacizumab); (MORE TO FOLLOW) Dow Jones Newswires
May 11, 2021 01:00 ET (05:00 GMT)
